Olema Pharmaceuticals (OLMA) Stock Statistics & Valuation Metrics

Olema Pharmaceuticals has a market cap or net worth of $1.31B. The enterprise value is $1.27B.

Olema Pharmaceuticals has 87,156,960 shares outstanding. The number of shares has decreased by -2.65% in one year.

Olema Pharmaceuticals’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -37.02%.

The current PE Ratio of Olema Pharmaceuticals is ―. Olema Pharmaceuticals’s PEG ratio is 0.89.

In the last 12 months, Olema Pharmaceuticals had revenue of 0.00 and earned -162.45M in profits. Earnings per share was -1.87.

In the last 12 months, operating cash flow was -146.72M and capital expenditures 0.00, giving a free cash flow of -146.72M billion.

Olema Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Olema Pharmaceuticals upcoming earnings date is May 12, 2026, After Close (Confirmed).

Olema Pharmaceuticals as a current ratio of 9.95, with Debt / Equity ratio of 0.25%

In the past 12 months, Olema Pharmaceuticals has paid 0.00 in taxes.

Olema Pharmaceuticals EV to EBITDA ratio is -11.94, with an EV/FCF ratio of -14.50.

Olema Pharmaceuticals has $505.44M in cash and marketable securities with $1.19M in debt, giving a net cash position of $504.24M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Olema Pharmaceuticals is $42.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy